All In Biotech

Drug Trial Radar · NCT01400217

Qvar Versus Clenil, a General Practice Research Database Study

HFA Beclomethasone in Asthma, a General Practice Research Database Study: Real-life Observational Evaluation of Extra-fine With Standard Particle Size Beclometasone Dipropionate Using the Propellant Hydrofluoroalkane 134a for the Management of Asthma in a Representative UK Primary Care Population

Last checked: Nov 19, 2026Latest source record: Oct 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56,985

Actual

Start

Jan 1991

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Lead sponsor
Research in Real-Life LtdResearch network
Sponsor type
Research network
Collaborators
Teva Branded Pharmaceutical Products R&D, Inc.
First posted
Jul 22, 2011

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 4 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the absolute and relative effectiveness of asthma management in patients on inhaled corticosteroid (ICS) maintenance therapy as either extra-fine-particle or larger-particle formulation beclomethasone dipropionate (BDP) via metered-dose inhalers (MDIs) using the propellant hydrofluoroalkane propellant (HFA-BDP), namely Qvar® MDI compared with Clenil® MDI.

Conditions

  • Asthma

Interventions

  • extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhalerDrug

    IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug

  • standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhalerDrug

    IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severe asthma exacerbation (ATS/ERS based defn)Time frame: 1 year
  2. Primary composite asthma controlTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research in Real Life Ltd

    Cawston, Norfolk, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.